FDA approves Warner Chilcott's ACTONEL for postmenopausal osteoporosis

NewsGuard 100/100 Score
Oct 11 2010

Warner Chilcott plc (Nasdaq: WCRX) today announced that the United States Food and Drug Administration (FDA) has approved its next generation ACTONEL® (risedronate sodium) product for the treatment of postmenopausal osteoporosis in the United States.  The product will be marketed as ATELVIA™ (risedronate sodium) delayed-release tablets.  

"The approval of ATELVIA represents an exciting addition to the ACTONEL franchise, as well as our women's healthcare product portfolio.  We believe the dosing convenience of ATELVIA sets it apart from other treatment options for osteoporosis patients and provides an opportunity to regain market share in the U.S. in this segment," said Roger Boissonneault, President and CEO of Warner Chilcott.

The Company anticipates the commercial launch of ATELVIA in early 2011.

Source:

Warner Chilcott plc

Posted in: Women's Health News | Pharmaceutical News

Tags: , , , , , , ,

Comments (0)

Suggested Reading

Adolescent sports participation associated with higher bone mineral density in old age
Canadian researchers aim to reduce chronic inflammation and comorbidities in HIV patients
Osteoporosis model rats show improved healing with FGF-2 treatment
Living near green spaces linked to higher bone density and lower osteoporosis risk
Sesame oil supplementation: a potential breakthrough in postmenopausal osteoporosis prevention?
Tea consumption increases bone density and reduces the risk of osteoporosis
How residential green spaces impact bone health and osteoporosis risk
Living near green spaces linked to stronger bones in young children

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
(Logout)
Post

Newsletters you may be interested in

See all Newsletters »

Terms

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

Provide Feedback

You might also like...
Higher doses of topical corticosteroids linked to increased risks of osteoporosis and bone fractures